John K. C. Lim

1.8k total citations
26 papers, 1.1k citations indexed

About

John K. C. Lim is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John K. C. Lim has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John K. C. Lim's work include Lung Cancer Treatments and Mutations (6 papers), HER2/EGFR in Cancer Research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). John K. C. Lim is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), HER2/EGFR in Cancer Research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). John K. C. Lim collaborates with scholars based in United States, Australia and South Korea. John K. C. Lim's co-authors include Sean O’Brien, Caroline B. Ho, Kenna Anderes, Chris Proffitt, William G. Rice, Adam Siddiqui-Jain, Denis Drygin, Daniel D. Von Hoff, Michael K. Schwaebe and Katy Trent and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

John K. C. Lim

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John K. C. Lim United States	13	835	266	100	98	68	26	1.1k
Chudi Ndubaku United States	12	500 0.6×	282 1.1×	87 0.9×	116 1.2×	32 0.5×	22	932
Zena Wilson United Kingdom	11	458 0.5×	316 1.2×	123 1.2×	107 1.1×	62 0.9×	21	742
Guangan He United States	14	507 0.6×	319 1.2×	119 1.2×	66 0.7×	77 1.1×	26	846
Linda Kessler United States	14	746 0.9×	352 1.3×	75 0.8×	137 1.4×	106 1.6×	38	1.1k
Jean‐Damien Charrier United Kingdom	11	885 1.1×	565 2.1×	122 1.2×	128 1.3×	55 0.8×	22	1.1k
Masanori Okaniwa Japan	16	886 1.1×	229 0.9×	118 1.2×	250 2.6×	108 1.6×	26	1.4k
Dirk Weber Germany	14	281 0.3×	305 1.1×	66 0.7×	132 1.3×	142 2.1×	35	709
Naniye Mallı Cetinbas Canada	8	573 0.7×	226 0.8×	129 1.3×	122 1.2×	84 1.2×	12	822
Kumaresan Ganesan India	16	574 0.7×	239 0.9×	224 2.2×	61 0.6×	132 1.9×	45	967
Elgilda Musi United States	13	450 0.5×	304 1.1×	53 0.5×	102 1.0×	148 2.2×	25	852

Countries citing papers authored by John K. C. Lim

Since Specialization

Citations

This map shows the geographic impact of John K. C. Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John K. C. Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John K. C. Lim more than expected).

Fields of papers citing papers by John K. C. Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John K. C. Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John K. C. Lim. The network helps show where John K. C. Lim may publish in the future.

Co-authorship network of co-authors of John K. C. Lim

This figure shows the co-authorship network connecting the top 25 collaborators of John K. C. Lim. A scholar is included among the top collaborators of John K. C. Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John K. C. Lim. John K. C. Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moskowitz, Alison J., A. Harstrick, Sheena Pinto, et al.. (2023). AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE). Blood. 142(Supplement 1). 4855–4855. 9 indexed citations

Khanal, Rashmi, Jennifer N. Saultz, Umar Farooq, et al.. (2022). Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood. 140(Supplement 1). 12742–12743. 1 indexed citations

Khot, Amit, Natalie Brajanovski, Donald P. Cameron, et al.. (2019). First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discovery. 9(8). 1036–1049. 132 indexed citations

Zhai, Dayong, Evan Rogers, Xin Zhang, et al.. (2019). Abstract 1325: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses. Cancer Research. 79(13_Supplement). 1325–1325. 6 indexed citations

Zhai, Dayong, et al.. (2018). Abstract B185: TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026M. Molecular Cancer Therapeutics. 17(1_Supplement). B185–B185. 1 indexed citations

Drilon, Alexander, Sai‐Hong Ignatius Ou, Byoung Chul Cho, et al.. (2018). A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).. Journal of Clinical Oncology. 36(15_suppl). 2513–2513. 15 indexed citations

Zhai, Dayong, et al.. (2018). Abstract B186: TPX-0005, a polypharmacology inhibitor, overcomes ALK treatment resistance from acquired mutations, bypass signaling, and EMT. Molecular Cancer Therapeutics. 17(1_Supplement). B186–B186. 3 indexed citations

Lim, John K. C., et al.. (2017). Surgery for Cholesteatomatous Labyrinthine Fistula. Annals of Otology Rhinology & Laryngology. 126(3). 205–215. 14 indexed citations

Borad, Mitesh J., Joleen M. Hubbard, Do‐Youn Oh, et al.. (2017). A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma.. Journal of Clinical Oncology. 35(4_suppl). 294–294. 3 indexed citations

10.

Harrison, Simon J., Amit Khot, Natalie Brajanovski, et al.. (2015). A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM).. Journal of Clinical Oncology. 33(15_suppl). e22212–e22212. 10 indexed citations

11.

Siddiqui-Jain, Adam, Joshua Bliesath, Mayuko Omori, et al.. (2012). CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy. Molecular Cancer Therapeutics. 11(4). 994–1005. 86 indexed citations

12.

Bliesath, Joshua, Nanni Huser, Mayuko Omori, et al.. (2012). Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Letters. 322(1). 113–118. 59 indexed citations

13.

Drygin, Denis, Caroline B. Ho, Mayuko Omori, et al.. (2011). Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochemical and Biophysical Research Communications. 415(1). 163–167. 57 indexed citations

14.

Drygin, Denis, Adam Siddiqui-Jain, Sean O’Brien, et al.. (2009). Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis. Cancer Research. 69(19). 7653–7661. 462 indexed citations

15.

Marschke, Robert F., Eleni Andreopoulou, Daniel D. Von Hoff, et al.. (2009). Abstract C39: Phase I clinical trial of CX-4945: A first-in-class orally administered small molecule inhibitor of protein kinase CK2. Molecular Cancer Therapeutics. 8(12_Supplement). C39–C39. 1 indexed citations

16.

Papadopoulos, Kyriakos P., Alain C. Mita, Alejandro D. Ricart, et al.. (2007). Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): a protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6. 10 indexed citations

17.

VanBrocklin, Henry F., et al.. (2005). Anilinodialkoxyquinazolines: Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Potential Tumor Imaging Probes. Journal of Medicinal Chemistry. 48(23). 7445–7456. 30 indexed citations

18.

Flood, Thomas C., et al.. (2000). Phosphine Ligand Exchange in Tetrakis(trimethylphosphine)(hydrido)osmium Anilides, Phenoxides, and Thiophenoxides. Examples of Anion Dissociation and of Labilization by Ligand π-Base Effects. Organometallics. 19(6). 1166–1174. 18 indexed citations

19.

Lim, John K. C., et al.. (2000). Synthesis of 4-(3′-[125I]iodoanilino)-6,7-dialkoxyquinazolines: radiolabeled epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Labelled Compounds and Radiopharmaceuticals. 43(12). 1183–1191. 8 indexed citations

20.

Bau, Robert, et al.. (1988). The crystal structure of tetrahydrothiamine and its Co(II) complex. Inorganica Chimica Acta. 150(1). 107–112. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact